Drugs /

lomustine

Back to Drugs List

Overview

Generic Name(s):
lomustine
Trade Name(s):
Prava, Lucostine, Cecenu, Ceenu, Belustine, Citostal, Lucostin, Belustin, and Lomeblastin
NCI Definition [1]:
A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis. This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing. Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)

Clinical Trials

View Clinical Trials for lomustine

Lomustine has been investigated in 18 clinical trials, of which 15 are open and 3 are closed. Of the trials investigating lomustine, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 4 are phase 1/phase 2 (3 open), 6 are phase 2 (5 open), 2 are phase 2/phase 3 (1 open), 3 are phase 3 (3 open), and 1 is no phase specified (1 open).

APC Loss, APC Mutation (germline), and CTNNB1 Exon 3 Mutation (somatic) are the most frequent biomarker inclusion criteria for lomustine clinical trials.

Glioblastoma, anaplastic astrocytoma, and malignant glioma are the most common diseases being investigated in lomustine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lomustine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Lomustine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lomustine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
CeeNU, Belustin, Belustine, Cecenu, Citostal, Lomeblastin, Lucostin, Lucostine, Prava, cyclohexylchloroethylnitrosourea, chloroethylcyclohexylnitrosourea, lomustine (substance), wr-139017, cyclohexyl chloroethyl nitrosourea, ccnu (cyclohexylchloroethylnitrosourea), 1-(2-chloroethyl)-3-cyclohexylnitrosourea, n-(2-chloroethyl)-n'-cyclohexyl-n-nitrosourea, lomustina, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, chloroethylcyclo- hexylnitrosourea, rb-1509, n-(2-chloroethyl)-n'-cyclohexyl-n-nitrosourea, chloroethylcyclo-hexylnitrosourea, 4595, 13010-47-4, ccnu - lomustine, urea, n-(2-chloroethyl)-n'-cyclohexyl-n-nitroso-, gleostine, lomustinum, 1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, chloroethylcyclohexylnitrosourea, ccnu, cinu, 79037, lomustine [chemical/ingredient], lomustine (product), n-(2-chloroethyl)-n'-cyclohexyl-n-nitrosourea, 1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, lomustine
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C617
SNOMED ID [1]:
C-78120

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.